Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.

Amarin Corporation plc

Amarin ( ($AMRN) ) has issued an announcement. On March 25, 2026, Amarin’s board moved to streamline its governance structure by reducing the size ...

Current Quarter	$-2.71	Next Quarter	$-2.33
Current Year	$-7.04	Next Year	$-5.39
QoQ Growth	+14.0%	YoY Growth	+23.4%
3Y EPS CAGR	-35.7%	Target Price	$12.00
Consensus	Buy	Upside	-18.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMRN	$14.78	0.00%	63.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMRN	$14.78	0%	63.05K
3
4
5
6

AMRN

AMRN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Amarin Corporation plc Data in Excel

Get Amarin Corporation plc Data in Excel